263 related articles for article (PubMed ID: 32472959)
1. Multifarious roles of mTOR signaling in cognitive aging and cerebrovascular dysfunction of Alzheimer's disease.
Uddin MS; Rahman MA; Kabir MT; Behl T; Mathew B; Perveen A; Barreto GE; Bin-Jumah MN; Abdel-Daim MM; Ashraf GM
IUBMB Life; 2020 Sep; 72(9):1843-1855. PubMed ID: 32472959
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment.
Van Skike CE; Jahrling JB; Olson AB; Sayre NL; Hussong SA; Ungvari Z; Lechleiter JD; Galvan V
Am J Physiol Heart Circ Physiol; 2018 Apr; 314(4):H693-H703. PubMed ID: 29351469
[TBL] [Abstract][Full Text] [Related]
3. mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging.
Van Skike CE; Lin AL; Roberts Burbank R; Halloran JJ; Hernandez SF; Cuvillier J; Soto VY; Hussong SA; Jahrling JB; Javors MA; Hart MJ; Fischer KE; Austad SN; Galvan V
Aging Cell; 2020 Jan; 19(1):e13057. PubMed ID: 31693798
[TBL] [Abstract][Full Text] [Related]
4. A Perfect sTORm: The Role of the Mammalian Target of Rapamycin (mTOR) in Cerebrovascular Dysfunction of Alzheimer's Disease: A Mini-Review.
Van Skike CE; Galvan V
Gerontology; 2018; 64(3):205-211. PubMed ID: 29320772
[TBL] [Abstract][Full Text] [Related]
5. mTOR Attenuation with Rapamycin Reverses Neurovascular Uncoupling and Memory Deficits in Mice Modeling Alzheimer's Disease.
Van Skike CE; Hussong SA; Hernandez SF; Banh AQ; DeRosa N; Galvan V
J Neurosci; 2021 May; 41(19):4305-4320. PubMed ID: 33888602
[TBL] [Abstract][Full Text] [Related]
6. mTOR drives cerebral blood flow and memory deficits in LDLR
Jahrling JB; Lin AL; DeRosa N; Hussong SA; Van Skike CE; Girotti M; Javors M; Zhao Q; Maslin LA; Asmis R; Galvan V
J Cereb Blood Flow Metab; 2018 Jan; 38(1):58-74. PubMed ID: 28511572
[TBL] [Abstract][Full Text] [Related]
7. Vascular mTOR-dependent mechanisms linking the control of aging to Alzheimer's disease.
Galvan V; Hart MJ
Biochim Biophys Acta; 2016 May; 1862(5):992-1007. PubMed ID: 26639036
[TBL] [Abstract][Full Text] [Related]
8. Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature.
Caccamo A; De Pinto V; Messina A; Branca C; Oddo S
J Neurosci; 2014 Jun; 34(23):7988-98. PubMed ID: 24899720
[TBL] [Abstract][Full Text] [Related]
9. Oxidative Stress and Decreased Mitochondrial Superoxide Dismutase 2 and Peroxiredoxins 1 and 4 Based Mechanism of Concurrent Activation of AMPK and mTOR in Alzheimer's Disease.
Majd S; Power JHT
Curr Alzheimer Res; 2018; 15(8):764-776. PubMed ID: 29473507
[TBL] [Abstract][Full Text] [Related]
10. Physical Activity Alleviates Cognitive Dysfunction of Alzheimer's Disease through Regulating the mTOR Signaling Pathway.
Kou X; Chen D; Chen N
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30934958
[TBL] [Abstract][Full Text] [Related]
11. Differential activation of mTOR complex 1 signaling in human brain with mild to severe Alzheimer's disease.
Sun YX; Ji X; Mao X; Xie L; Jia J; Galvan V; Greenberg DA; Jin K
J Alzheimers Dis; 2014; 38(2):437-44. PubMed ID: 23979023
[TBL] [Abstract][Full Text] [Related]
12. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
Yew B; Nation DA;
Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149
[TBL] [Abstract][Full Text] [Related]
13. PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease.
O' Neill C
Exp Gerontol; 2013 Jul; 48(7):647-53. PubMed ID: 23470275
[TBL] [Abstract][Full Text] [Related]
14. mTOR in Alzheimer disease and its earlier stages: Links to oxidative damage in the progression of this dementing disorder.
Perluigi M; Di Domenico F; Barone E; Butterfield DA
Free Radic Biol Med; 2021 Jun; 169():382-396. PubMed ID: 33933601
[TBL] [Abstract][Full Text] [Related]
15. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD.
Tramutola A; Triplett JC; Di Domenico F; Niedowicz DM; Murphy MP; Coccia R; Perluigi M; Butterfield DA
J Neurochem; 2015 Jun; 133(5):739-49. PubMed ID: 25645581
[TBL] [Abstract][Full Text] [Related]
16. Deciphering Alzheimer's Disease Pathogenic Pathway: Role of Chronic Brain Hypoperfusion on p-Tau and mTOR.
de la Torre JC
J Alzheimers Dis; 2021; 79(4):1381-1396. PubMed ID: 33459641
[TBL] [Abstract][Full Text] [Related]
17. Targeting the mTOR signaling network for Alzheimer's disease therapy.
Wang C; Yu JT; Miao D; Wu ZC; Tan MS; Tan L
Mol Neurobiol; 2014 Feb; 49(1):120-35. PubMed ID: 23853042
[TBL] [Abstract][Full Text] [Related]
18. Endothelial Dysfunction in Neurodegenerative Diseases.
Fang YC; Hsieh YC; Hu CJ; Tu YK
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769234
[TBL] [Abstract][Full Text] [Related]
19. Impaired cerebral blood flow in type 2 diabetes mellitus - A comparative study with subjective cognitive decline, vascular dementia and Alzheimer's disease subjects.
Chau ACM; Cheung EYW; Chan KH; Chow WS; Shea YF; Chiu PKC; Mak HKF
Neuroimage Clin; 2020; 27():102302. PubMed ID: 32521474
[TBL] [Abstract][Full Text] [Related]
20. [Effect of mammalian target of rapamycin on cognitive dysfunction of Alzheimer's Disease via regulating Homer3].
Huang YQ; Liu XG; Zhang L; Yu Y; Xue J; Sun JL
Zhonghua Yi Xue Za Zhi; 2020 May; 100(17):1336-1340. PubMed ID: 32375443
[No Abstract] [Full Text] [Related]
[Next] [New Search]
